ThinkStock PhotosICICI Securities has buy call on with a target price of Rs 18497. The current market price of Abbott India Ltd. is Rs 15978.35.
Abbott India Ltd., incorporated in the year 1944, is a Large Cap company (having a market cap of Rs 34113.31 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Standalone Total Income of Rs 1111.74 Crore, up .12 % from last quarter Total Income of Rs 1110.38 Crore and up 12.37 % from last year same quarter Total Income of Rs 989.33 Crore. Company reported net profit after tax of Rs 152.47 Crore in latest quarter.
Investment Rationale
The brokerage raises sales and earnings estimates by 1-2% and 0-2% respectively for FY22E-FY23E to reflect higher growth in key brands. It maintains BUY with a revised target price of Rs18,497/share based on 42xFY23E EPS (earlier: Rs18,195/share). Key downside risks are: addition of key drugs in NLEM, product concentration, government intervention, and presence of unlisted promoter company.
Promoter/FII Holdings
Promoters held 75 per cent stake in the company as of March 31, 2021, while FIIs held 1.9 per cent, DIIs 4.6 per cent and public and others 18.5 per cent.
(Views and recommendations given in this section are the analysts' own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.)
Abbott India Ltd., incorporated in the year 1944, is a Large Cap company (having a market cap of Rs 34113.31 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Standalone Total Income of Rs 1111.74 Crore, up .12 % from last quarter Total Income of Rs 1110.38 Crore and up 12.37 % from last year same quarter Total Income of Rs 989.33 Crore. Company reported net profit after tax of Rs 152.47 Crore in latest quarter.
Investment Rationale
The brokerage raises sales and earnings estimates by 1-2% and 0-2% respectively for FY22E-FY23E to reflect higher growth in key brands. It maintains BUY with a revised target price of Rs18,497/share based on 42xFY23E EPS (earlier: Rs18,195/share). Key downside risks are: addition of key drugs in NLEM, product concentration, government intervention, and presence of unlisted promoter company.
Promoter/FII Holdings
Promoters held 75 per cent stake in the company as of March 31, 2021, while FIIs held 1.9 per cent, DIIs 4.6 per cent and public and others 18.5 per cent.
(Views and recommendations given in this section are the analysts' own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.)
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.